Cardiorenalmetabolic

Varsha Tanguturi, MD, cardiologist and DETECT AS investigator, presented new data on how the findings she and her colleagues saw indicate almost universal increases in rates of aortic valve replacement in patients with severe aortic stenosis (AS), across both provider and patient groups.

Khush Kharidia, MD, a third-year internal medicine resident at UT Southwestern, presented the oral abstract, “Evaluating the Quality, Accuracy and Health Impact of Cholesterol-Related Content on TikTok: A Social Media Analysis,” at ASPC 2025 Congress on CVD Prevention.

Alexandra M. Trevino, MD, of Northwestern Medicine presented the oral abstract, "Trends in New-Onset Hypertensive Disorders of Pregnancy Among US Adults by Place of Birth and Hispanic Ethnic Origin Group," on day 1 of the ASPC Congress on CVD Prevention.

A meta-analysis reveals a significant link between chronic kidney disease (CKD) and gastroesophageal reflux disease (GERD), highlighting the need for increased screening and awareness.

Nurses enhance chronic kidney disease (CKD) care by implementing a palliative CKD care framework, addressing barriers, and promoting patient-centered supportive strategies globally.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events, based on FINEARTS-HF trial results.

Avoiding downstream testing ultimately makes it cheaper for whoever is footing the bill, says Merrill H. Stewart, MD, Ochsner Health.

Merrill Stewart, MD, Ochsner Health, says insufficient funding from CMS for graduate medical education (GME) limits the ability to expand cardiology fellowships and contributes to the nationwide physician shortage.

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital.

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.

Antoine Keller, MD, argued the value of grounding health care policy in equity as clinicians prepare for a changing health care landscape in the coming years.

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

Findings from the interviews offer insight into potential strategies for reducing binge eating among patients who experience food insecurity.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.